The US Food and Drug Administration has approved an antibiotic drug that treats acute bacterial infections in patients over 65.
A trial of the antibiotic Ciprofloxacin (Cipro) has been halted following a US court decision which invalidates the product’s label and opens the door for doctors to prescribe antibiotics as well.
The US Food and Drug Administration (FDA) announced today that the agency will temporarily ban the drug after it failed to meet required safety and efficacy standards.
Cipro is classified as a quinolone antibiotic and is a brand name for the antibiotic fluoroquinolone.
The FDA announced the drug’s approval yesterday, saying it was an “approved,” “first-line therapy” for treating uncomplicated acute bacterial infections. The agency said the drug was effective against a broad range of bacteria and is approved for use in hospitals and outpatient clinics. In its statement, the FDA said the drug was not effective against infections of the skin and soft tissue.
“The FDA’s decision will continue to require that it make available evidence to the public that, in the absence of clinical trials, the safety and efficacy of Cipro will not be demonstrated to physicians. The FDA must now make these necessary safety and efficacy statements to ensure patients receive the full benefit of the drug,” said John Smith, F. D. A.
Smith, an analyst at Lehman Brothers, toldThe New York Timesthat Cipro was approved by the FDA because of its proven effectiveness and safety. He said the FDA has received a lot of negative feedback regarding the drug and that it will take time to review the safety and efficacy of Cipro.
In a letter to the FDA on Wednesday, Dr. William D. Lees, M. D., a professor of medicine and clinical medicine at the University of North Carolina, Chapel Hill, said: “We are continuing to evaluate data from several clinical trials with Cipro, and we are not certain that there is enough evidence to support their use. We have also not been able to establish that Cipro is safe or effective for the treatment of bacterial infections.”
The FDA said the agency is taking the decision because the safety and efficacy of the antibiotic Cipro has not been established. “We are pleased with the results of the Cipro trial and hope that we will continue to make the necessary safety and efficacy statements available to patients and to healthcare providers,” said Dr. Lees.
The FDA also said it was reviewing clinical data from the Cipro trial to determine if it should be suspended. It said the drug’s safety and efficacy have not been established by the FDA.
Cipro is a quinolone antibiotic and is a brand name for the antibiotic fluoroquinolone.Originally Published: February 11, 2013 at 12:04 PM EDT
A study of the antibiotic Cipro has been halted after a US court decision which invalidates the product’s label and opens the door for doctors to prescribe antibiotics as well.
A trial of the antibiotic Cipro has been halted following a US court decision which invalidates the product’s label and opens the door for doctors to prescribe antibiotics as well.
The FDA announced today the agency will temporarily ban the drug after it failed to meet required safety and efficacy standards.
The US Food and Drug Administration announced today the agency will temporarily ban the drug after it failed to meet required safety and efficacy standards.“This is an important step in protecting patients and our healthcare system from antibiotic resistance,” said Dr. Richard C. Wolfe, FDA’s Chief of Staff. “We have had a lot of negative feedback about Cipro. We are continuing to review the data to make sure that we make the necessary safety and efficacy statements available to patients and to physicians.”
The FDA said it was reviewing data from the Cipro trial and that the drug was not effective against a broad range of bacteria and is approved for use in hospitals and outpatient clinics.
Wolfe said there was no basis for the FDA to recommend the discontinuation of Cipro.
VIDEO
Ciprofloxacin is a powerful antibiotic medication commonly used to treat various bacterial infections, including urinary tract infections (UTIs), respiratory tract infections (such as bacterial pneumonia), and others. It belongs to the fluoroquinolone class and works by inhibiting DNA gyrase, an enzyme that is essential for the synthesis of bacterial DNA.
Ciprofloxacin is a prescription medication that contains the active ingredient, Cipro, which belongs to a class of antibiotics known as DNA gyrase inhibitors. It works by targeting the replication of bacteria, thereby preventing their growth and multiplication. This action not only helps in fighting off infections but also helps to alleviate symptoms like fever, fatigue, and swelling around the area. Ciprofloxacin is commonly prescribed for the treatment of various bacterial infections, including urinary tract infections (UTIs) and respiratory tract infections (such as bacterial pneumonia). It is important to follow the prescribed dosage and complete the full course of treatment to ensure the infection is completely eradicated. Ciprofloxacin can also be prescribed for certain other uses, such as anti-diarrhea or asthma management.
The main benefits of taking Ciprofloxacin include its ability to effectively treat various bacterial infections, including urinary tract infections (UTIs), respiratory tract infections (such as bacterial pneumonia), and others.
Ciprofloxacin works by inhibiting the replication of bacteria, which helps to combat bacterial infections. This inhibition enhances the bacterial cells’ ability to replicate and repair, thereby reducing the likelihood of the infection developing resistance. By targeting the gyrase enzyme, Ciprofloxacin effectively inhibits the replication of bacteria, thus eradicating the infection.
Ciprofloxacin should be taken orally, with or without food, as directed by a healthcare professional. Swallow the tablets whole with a drink of water. Do not break, crush, or chew them.
Like any medication, Ciprofloxacin can cause side effects. However, not everyone will experience these side effects, and it is important to speak with a healthcare professional before using this medication. The most common side effects of Ciprofloxacin include:
Ciprofloxacin should be used with caution in children and adolescents (12 years and older). It is important to inform your doctor about any prescription or over-the-counter (OTC) drugs, over-the-counter medicines, and supplements you are taking before starting Ciprofloxacin. Inform your doctor about any prescription or OTC medications you are taking because Ciprofloxacin can interact with these drugs and cause serious side effects.
The aim of this study was to evaluate the effect of the quinolone antibiotic ciprofloxacin on the pharmacokinetics of the marketed and marketed drugs in healthy volunteers. The study was carried out in a laboratory with the purpose to assess the pharmacokinetic parameters of ciprofloxacin and the oral ciprofloxacin dose. The study was approved by the Animal Care and Use Committee of the Faculty of Veterinary Medicine of the National University of Hong Kong.
We conducted a single dose study in male healthy volunteers. We divided the volunteers into 5 groups, i.e., 1 group (ciprofloxacin (10 mg/kg), 1 group (ciprofloxacin 2.5 mg/kg, 2.5 mg/kg, 2.5 mg/kg and 1 mg/kg) in the 1 mg/kg group; 1 group (ciprofloxacin 0.5 mg/kg and ciprofloxacin 0.3 mg/kg), 2 groups (ciprofloxacin 0.5 mg/kg and ciprofloxacin 0.9 mg/kg) and 2 groups (ciprofloxacin 0.9 mg/kg and ciprofloxacin 1 mg/kg).
In each group, the volunteers took 1.0 mg/kg ciprofloxacin (equivalent to 1.0 mg/kg). The volunteers also took 1.0 mg/kg ciprofloxacin 2.5 mg/kg. After that, the volunteers took a second dose of the ciprofloxacin at a dose of 0.5 mg/kg and the ciprofloxacin at a dose of 2.5 mg/kg, respectively. We performed a randomisation and sampling procedure in the 2 groups (ciprofloxacin 0.5 mg/kg and ciprofloxacin 0.9 mg/kg), 2 groups (ciprofloxacin 0.9 mg/kg and ciprofloxacin 1 mg/kg) and 2 groups (ciprofloxacin 0.5 mg/kg and ciprofloxacin 1 mg/kg).
After that, we took the oral ciprofloxacin at the same dose as that of the oral ciprofloxacin, i.e., 1.0 mg/kg and 2.5 mg/kg, respectively. The oral ciprofloxacin was administered orally at the same dose in the 2 groups. We followed the administration schedule in the 4 groups. We followed the route of administration in the 6 groups. The ciprofloxacin (0.5 mg/kg and 0.9 mg/kg) and the oral ciprofloxacin (0.5 mg/kg and 2.5 mg/kg) were administered as either 0.5 or 2.5 mg/kg, respectively. The ciprofloxacin and oral ciprofloxacin doses were measured as follows: The ciprofloxacin dose was calculated according to the body weight and the formula: the ciprofloxacin dose of 0.5 mg/kg and the oral ciprofloxacin dose of 0.9 mg/kg, was calculated as: the ciprofloxacin dose of 2.5 mg/kg and the oral ciprofloxacin dose of 2.9 mg/kg. The oral ciprofloxacin dose was calculated according to the body weight and the formula: the oral ciprofloxacin dose of 0.9 mg/kg and the oral ciprofloxacin dose of 1 mg/kg. The oral ciprofloxacin dose of 2.5 mg/kg and the oral ciprofloxacin dose of 2.9 mg/kg were calculated as the oral ciprofloxacin dose of 2.5 mg and the oral ciprofloxacin dose of 3.0 mg/kg. The study was carried out in accordance with the principles of the Declaration of Helsinki and its adaptation to human clinical practice.
The area under the curve of the ciprofloxacin at the doses of 0.5, 2.5, and 3.0 mg/kg (ciprofloxacin 0.5 mg/kg) and 0.9 mg/kg (ciprofloxacin 0.
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Generic name: Ciprofloxacincillin creamGUARRIER CITRATE| Class | Ciprofloxacincillin |
| Package Size | 12gm |
| Packaging Type | Strip |
| Composition | |
| Formulations | Ciprofloxacin |
| MedsGo Class B |
There are no specific guidelines or precautions for use w/ dairy products. Wpected clinicians must be aware of the potential for gastrointestinal discomfort, hypersensitivity, renal or hepatic impairment and potential QT interval prolongation. Ciprofloxacin may cause QT prolongation (see Precautions).
Patients with pre-existing pre-existing cardiovascular (e.g. MI, stroke) or cerebrovascular (e.g. stroke) diseases should be advised to avoid the concomitantly use of ciprofloxacin if they have any risk factors for QT interval prolongation, such as MI, MI within the last six months, hypotension, beta-blockers or diabetes, and history of tendon disorders. Avoid the concomitantly use of ciprofloxacin if you have any pre-existing connective tissue disorders, including aneurysms, traumatic brain injury, cerebral lupus erythematosus or leukemia. Ciprofloxacin should be used with caution in these patients.
The safety and efficacy of ciprofloxacin have not been established in controlled clinical studies w/ psychiatric, nutritional, or neurological disorders. Quinolones are potent broad-spectrum quinaprilants that act primarily on the bacterial end of the spectrum. Plasma levels of quinolones may be higher w/ the concentration of ciprofloxacin in the blood serum.
Stade de France Pharmacy